Key clinical point: The effects of dual antiplatelet therapy (DAPT) were similar with 1-month DAPT followed by clopidogrel monotherapy were similar to those with 3-month DAPT followed by aspirin monotherapy.
Major finding: The primary endpoint of a composite of cardiovascular death, myocardial infarction, stroke, definite stent thrombosis and TIMI major/minor bleeding was not significantly different between a 1-month and 3-month trial involving DAPT plus clopidogrel or aspirin (1.7% vs. 1.6%).
Study details: The data come from a prospective study of 1,480 patients in one study and 1,339 in a second study.
Disclosures: The study was supported by Abbott Vascular. Several study coauthors are advisory board members of Abbott Vascular. Lead author Dr. Natsuaki had no financial conflicts to disclose.
Natsuaki M et al. Circ J. 2020 Jul 19. doi: 10.1253/circj.CJ-20-0298.